Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 8, 2004, Pages 2666-2673

  Cursiefen, Claus ^a,d   Cao, Jingtai ^b   Chen, Lu ^a   Liu, Ying ^a   Maruyama, Kazuichi ^a   Jackson, David ^c   Kruse, Friedrich E ^d   Wiegand, Stanley J ^b   Dana, M Reza ^a   Streilein, J Wayne ^a   Stein Streilein, Joan ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CELL MARKER; IMMUNOGLOBULIN FC FRAGMENT; LYVE 1 PROTEIN; RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN TRAP R1R2;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; HEMANGIOGENESIS; HISTOGENESIS; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; INCIDENCE; ISOGRAFT; KERATOPLASTY; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD31; CORNEA; CORNEAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLYCOPROTEINS; GRAFT SURVIVAL; KERATOPLASTY, PENETRATING; LYMPHANGIOGENESIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3242881656     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-1380     Document Type: Article

References (32)

1. Streilein JW, Yamada J, Dana MR, Ksander BR. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc. 1999;31:1472-1475.
2. Küchle M, Cursiefen C, Nguyen NX, et al. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol. 2002;240:580-584.
3. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2494.
4. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies: collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101:1536-1547.
5. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci. 1995;36:2176-2185.
6. Cursiefen C, Schlötzer-Schrehardt U, Küchle M, et al. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci. 2002;43:2127-2135.
7. Cursiefen C, Chen L, Dana MR, Streilein JW, Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea. 2003;22:273-281.
8. Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med. 2002;195:259-268.
9. Cursiefen C, Martus P, Nguyen NX, Langenbucher A, Seitz B, Küchle M. Corneal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty. Cornea. 2002;21:648-652.
10. Dana MR, Schaumberg DA, Kowal VO, et al. Corneal neovascularization after penetrating keratoplasty. Cornea. 1995;14:604-609.
11. Cursiefen C, Wenkel H, Martus P, et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2001;239:514-521.
12. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
13. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54:694-704.
14. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789-801.
15. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99:11393-11398.
16. Cursiefen C, Chen L, Borges L, et al. VEGF-A stimulates lymph- and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040-1050.
17. Shen H, Clauss M, Ryan J, et al. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood. 1993;81:2767-2773.
18. Lee TH, Avraham H, Lee SH, Avraham S. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem. 2002;277:10445-10451.
19. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001;42:1293-1298.
20. Yamagami S, Dana MR, Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea. 2002;21:405-409.
21. Streilein JW, Bradley D, Sano Y, Sonoda Y. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest Ophthalmol Vis Sci. 1996;37:413-424.
22. Sonoda Y, Sano Y, Ksander B, Streilein JW. Characterization of cell-mediated immune responses elicited by orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci. 1995;36:427-434.
23. Sonoda Y, Streilein JW. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J Immunol. 1993;150:1727-1734.
24. Slegers TP, van der Gaag R, van Rooijen N, van Rij G, Streilein JW. Effect of local macrophage depletion on cellular immunity and tolerance evoked by corneal allografts. Curr Eye Res. 2003;26:73-79.
25. Slegers TP, van Rooijen N, van Rij G, van der Gaag R. Delayed graft rejection in pre-vascularised corneas after subconjunctival injection of clodronate liposomes. Curr Eye Res. 2000;20:322-324.
26. Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBOJ. 2001;20:1223-1231.
27. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA. 2002;99:8868-8873.
28. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 2000;19:5598-5605.
29. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/ vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196:1497-1506.
30. Reinders MEJ, Fang JC, Wong W, Ganz P, Briscoe DM. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation. 2003;76:224-230.
31. Yatoh S, Kawakami Y, Imai M, et al. Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat. Transplantation. 1998;66:1519-1524.
32. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004;45:1117-1124.